GLAUCOMA 360

Panel discusses IOP monitoring, drug delivery, data collection

ICYMI: Nir Israeli, co-founder and CEO of Sanoculis discusses the company's new alternative surgical procedure for glaucoma designed to create a single-patient-use sterile tool and a multi-use external machine.

For many physicians, “moral injury” may be actual issue

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

High-level observations for how the latest developments can help glaucoma specialists solve problems to achieve the utmost in patient care

Besides traditional medications, here are some of the many novel approaches to treat patients with glaucoma

There are other mimickers of NTG that should be kept in mind

New products increase the chance of early diagnosis

ICYMI: Daria Lemann Blumenthal, CEO of BELKIN Laser, Ltd., discusses the company's current initiative of developing an automated one-second laser therapy for glaucoma called direct selective laser trabeculoplasty (DSLT).

New therapies on the horizon offer options for slowing progression

ICYMI: Yvonne Ou, MD, discusses her presentation on "Apps for the visually challenged," during the 2020 Glaucoma 360 annual meeting in San Francisco, California.

Novel technologies range from invasive to non-invasive approaches

Dale Heuer, MD discusses the importance of ophthalmologists identifying and providing more aggressive treatment care for patients with low/high risks of developing glaucoma.

ICYMI: Thomas Samuelson, MD,shares the key highlights from his presentation "Stents, trabs, and tubes: Decision-making in surgical glaucoma."

At Glaucoma 360 in San Francisco, Terri Pickering, MD, tolds attendees that artificial intelligence is a hot topic, with room to expand in the future.

At Glaucoma 360 in San Francisco, Terri-Diann Pickering, MD, told attendees that artificial intelligence is a hot topic, with room to expand in the future.

During the Glaucoma 360 annual meeting, Dale K. Heuer, MD, delivered the Shaffer-Hetherington-Hoskins Lecture Keynote address, titled “Risk Factors for Glaucoma Progression.”

Delivering the Drs. Henry and Frederick Sutro Memorial Lecture, David W. Parke II, MD, CEO of the American Academy of Ophthalmology, points out that patients and physicians can benefit from innovations in treatment. However, health policy and economics often can stand in the way of innovation.  

At Glaucoma 360, Diopter Corp. CEO Chris Adams discussed a contact lens device that has been found effective for treating glaucoma because it was engineered with vitamin E nano-barriers to extend drug release. 

The Charity event kicks off the three-day program, focusing on melding medicine, industry, research, and philanthropy.

Glaucoma 360 will kick off Thursday in San Francisco. The progam includes speakers and panelists from more than 60 companies and institutions.